Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
European Journal of Neurology · 2026-06 · 33 (6)
DOI: 10.1111/ene.70654 ↗At a glance
Vergleichsstudie in European Journal of Neurology, published online on 2026-06-25. Written by María Garcés-Pellejero and 6 co-authors. Institution: Headache Unit, Neurology Department, Hospital Universitari Vall D'hebron, Barcelona, Spain. Major MEDLINE topics: Botulinum Toxins, Type A, Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists. 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Instituto de Salud Carlos III, Novartis.
Abstract (original language)
Objectives
To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups.
Results
A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05).
Conclusion
Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Headache Unit, Neurology Department, Hospital Universitari Vall D'hebron, Barcelona, Spain.
- Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID profiles: María Garcés-Pellejero, Marta Torres-Ferrús, Rut Mas-de-Les-Valls, Edoardo Caronna, Alicia Alpuente, Eulalia Giné-Ciprés, Patricia Pozo-Rosich
Funding
- Instituto de Salud Carlos III
- Novartis
Cite
APA
Garcés-Pellejero, M., Torres-Ferrús, M., Mas-de-Les-Valls, R., Caronna, E., Alpuente, A., Giné-Ciprés, E., & Pozo-Rosich, P. (2026). Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70654
Vancouver
Garcés-Pellejero M, Torres-Ferrús M, Mas-de-Les-Valls R, Caronna E, Alpuente A, Giné-Ciprés E, et al. Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70654
BibTeX
@article{GarcsPellejero2026,
author = {Garcés-Pellejero, María and Torres-Ferrús, Marta and Mas-de-Les-Valls, Rut and Caronna, Edoardo and Alpuente, Alicia and Giné-Ciprés, Eulalia and Pozo-Rosich, Patricia},
title = {Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {6},
doi = {10.1111/ene.70654}
}
EUVIMED